I-MAB (IMAB) ROE % Adjusted to Book Value : -78.41% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB ROE % Adjusted to Book Value?

I-MAB's ROE % for the quarter that ended in Sep. 2024 was -36.07%. I-MAB's PB Ratio for the quarter that ended in Sep. 2024 was 0.46. I-MAB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -78.41%.

I-MAB ROE % Adjusted to Book Value Historical Data

The historical data trend for I-MAB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB ROE % Adjusted to Book Value Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

6.45

-8.77

-77.95

-98.84

I-MAB Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial														-88.74	-	-175.35	73.61	-78.41

Competitive Comparison of I-MAB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, I-MAB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where I-MAB's ROE % Adjusted to Book Value falls into.

I-MAB ROE % Adjusted to Book Value Calculation

I-MAB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-62.27%	/	0.63
	=	-98.84%

I-MAB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-36.07%	/	0.46
	=	-78.41%

I-MAB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of I-MAB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).